journal article·2025-10-08

Polymer-grafted porous silicon nanoparticles for enhanced siRNA delivery

Zahra Abousalman-Rezvani, Pouya Dehghankelishadi, Lars Esser, Nicolas H. Voelcker

Surface Innovations· Volume 13· Issue 5-6
Publisher page

Abstract

Small interfering RNA (siRNA) shows promise for cancer treatment but faces biological barriers limiting its effective clinical use. To overcome these limitations and enhance siRNA’s therapeutic potential, innovative drug delivery systems are needed. Porous silicon nanoparticles (pSiNPs) are an attractive drug delivery system due to their high surface area, biodegradability, and tuneable porosity, although challenges with uncontrolled degradation, limited circulation time, and inefficient drug release remain. To address these limitations, we explored surface-initiated reversible addition-fragmentation chain transfer polymerisation to modify pSiNPs with poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) and poly(oligo(ethylene glycol) methacrylate) (POEGA). PDMAEMA, an ionisable polymer with tertiary amine groups, is protonated at physiological pH and facilitates strong electrostatic interactions with negatively charged siRNA, leading to an siRNA loading capacity up to 438 ± 21 μg/mg, but resulted in burst release. The addition of the outer POEGA block, with its hydrophilic and neutral properties, resulted in a similar loading efficiency and enabled a more controlled biphasic drug release kinetics, although it reduced cellular association. Both systems successfully protected the siRNA from RNAse degradation, showed good cytocompatibility, and successful delivered siRNA targeting polo-like kinase 1 (PLK1). These results suggest that these polymer-coated pSiNPs offer a promising approach for siRNA delivery and gene therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanowire Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Monash University Monash Institute of Pharmaceutical Sciences, , Parkville, Victoria, ; Commonwealth Scientific and Industrial Research Organisation, Clayton, Victoria, Australia

Monash University Monash Institute of Pharmaceutical Sciences, , Parkville, Victoria,

Monash University Monash Institute of Pharmaceutical Sciences, , Parkville, Victoria, ; Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, Victoria, Australia; Department of Materials Science & Engineering, Monash University, Clayton, Victoria, Australia

References (34)

Show source-provided references
1. Where should siRNAs go: applicable organs for siRNA drugs10.1038/s12276-023-00998-y ↗
2. Therapeutic siRNA: state-of-the-art and future perspectives10.1007/s40259-022-00549-3 ↗
3. Clinical advances of siRNA therapeutics10.1002/jgm.3097 ↗
4. siRNA based drug design, quality, delivery and clinical translation10.1016/j.nano.2020.102239 ↗
5. Nanoparticle-mediated siRNA delivery systems for cancer therapy10.1002/VIW.20200111 ↗
6. Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer10.1039/D3TB00278K ↗
7. Polymeric nanoparticles for drug delivery10.1021/acs.chemrev.3c00705 ↗
8. Engineering siRNA therapeutics: challenges and strategies10.1186/s12951-023-02147-z ↗
9. siRNA therapeutics: insights, challenges, remedies and future prospects10.1080/17425247.2023.2251890 ↗
10. Cancer-targeting siRNA delivery from porous silicon nanoparticles10.2217/nnm.14.12 ↗
11. Tailoring the biodegradability of porous silicon nanoparticles10.1002/jbm.a.34294 ↗
12. Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy10.1016/j.actbio.2015.01.021 ↗
13. Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives10.1080/17425247.2017.1317245 ↗
14. Maximizing RNA loading for gene silencing using porous silicon nanoparticles10.1021/acsami.9b05577 ↗
15. Dendrimer toxicity: Let’s meet the challenge10.1016/j.ijpharm.2010.04.027 ↗
16. Mechanistic studies of in vitro cytotoxicity of poly (amidoamine) dendrimers in mammalian cells10.1016/j.taap.2010.08.016 ↗
17. Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin10.1039/D0BM01335H ↗
18. The promising nanocarrier for doxorubicin and siRNA co-delivery by PDMAEMA-based amphiphilic nanomicelles10.1021/acsami.5b11789 ↗
19. Core polymer optimization of ternary siRNA nanoparticles enhances in vivo safety, pharmacokinetics, and tumor gene silencing10.1016/j.biomaterials.2023.122098 ↗
20. Nonviral in vivo delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles10.1021/acsnano.2c12261 ↗
21. Aerosol delivery of star polymer-siRNA nanoparticles as a therapeutic strategy to inhibit lung tumor growth10.1016/j.biomaterials.2022.121539 ↗
22. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers10.1021/mp400049e ↗
23. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives10.1016/j.addr.2021.114079 ↗
24. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery10.1039/D1NR02065J ↗
25. Investigating oligo (ethylene glycol) methacrylate thermoresponsive copolymers10.1016/j.eurpolymj.2024.113266 ↗
26. Grafting of P (OEGA) onto magnetic nanoparticles using Cu (0) mediated polymerization: comparing grafting “from” and “to” approaches in the search for the optimal material design of nanoparticle MRI contrast agents10.1021/ma401250f ↗
27. Progress of porous silicon APTES-functionalization by FTIR investigations10.1016/j.apsusc.2015.01.107 ↗
28. Surface plasmons and visible light iniferter initiated polymerization for nanolocal functionalization of mesoporous separation layers10.1002/adfm.202009732 ↗
29. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer10.1117/1.2717137 ↗
30. Nano-assemblies from amphiphilic PnBA-b-POEGA copolymers as drug nanocarriers10.3390/polym13071164 ↗
31. Therapeutic siRNA: state of the art10.1038/s41392-020-0207-x ↗
32. Comprehensive review of mesoporous silica nanoparticles: drug loading, release, and applications as hemostatic agents10.1002/slct.202400450 ↗
33. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation10.1039/D2BM00181K ↗
34. Leopold · 2016 · 38310.1002/9781118978320.ch16 ↗